ReviewCureus2025
Exploring Internal Medicine by a Comparative Schematic Analysis of the Long-Term Outcomes of Anticoagulation Therapy in Atrial Fibrillation.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is a common arrhythmia with increased risks of stroke and other cardiovascular complications. This research examined the long-term outcomes of anticoagulation therapy in AF patients, focusing on its benefits for stroke reduction, bleeding hazards, and survival rates. Researchers conducted an extensive literature search that combined PubMed, Scopus, Web of Science, and Google Scholar to retrieve publications from 2015 to 2025. The search focused on keywords related to anticoagulation therapy and its connection to atrial fibrillation, stroke prevention, as well as both long-term outcomes and bleeding risks. The data extraction process was performed by two independent reviewers, while the assessment of study quality relied on the Newcastle-Ottawa Scale and the Cochrane Risk of Bias Tool. The evaluation of evidence quality followed the GRADE approach. A total of 12 studies were included in this review after full screening. Direct oral anticoagulants (DOACs) exhibited either matching or superior stroke prevention performance compared to warfarin while showing lower major bleeding occurrence according to existing research findings. Studies demonstrated that patients receiving DOACs had longer survival rates when examining death rates. The review demonstrated that anticoagulation medication shows strong clinical results as a treatment strategy for prolonged atrial fibrillation cases. Further research must expand with prolonged follow-up examinations to establish data on the safety and effectiveness of DOACs compared to warfarin and to create better guidelines for the long-term anticoagulation treatment of AF patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.